116 related articles for article (PubMed ID: 12665845)
1. Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation.
Bojko P; Hilger RA; Ruehm SG; Dirsch O; Seeber S; Scheulen ME
Bone Marrow Transplant; 2003 Mar; 31(6):487-91. PubMed ID: 12665845
[TBL] [Abstract][Full Text] [Related]
2. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
3. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.
Scheulen ME; Hilger RA; Oberhoff C; Casper J; Freund M; Josten KM; Bornhäuser M; Ehninger G; Berdel WE; Baumgart J; Harstrick A; Bojko P; Wolf HH; Schindler AE; Seeber S
Clin Cancer Res; 2000 Nov; 6(11):4209-16. PubMed ID: 11106234
[TBL] [Abstract][Full Text] [Related]
4. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.
Meden H; Wittkop Y; Kuhn W
Anticancer Res; 1997; 17(3C):2221-3. PubMed ID: 9216692
[TBL] [Abstract][Full Text] [Related]
5. Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer.
Hilger RA; Jacek G; Oberhoff C; Kredtke S; Baumgart J; Seeber S; Scheulen ME
Cancer Chemother Pharmacol; 2000; 45(6):483-8. PubMed ID: 10854136
[TBL] [Abstract][Full Text] [Related]
6. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation.
Koenigsmann M; Mohren M; Jentsch-Ullrich K; Franke A; Becker E; Heim M; Freund M; Casper J
Bone Marrow Transplant; 2004 Sep; 34(6):477-83. PubMed ID: 15286694
[TBL] [Abstract][Full Text] [Related]
7. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer.
Demirer T; Buckner CD; Appelbaum FR; Clift R; Storb R; Myerson D; Lilleby K; Rowley S; Bensinger WI
Bone Marrow Transplant; 1996 May; 17(5):769-74. PubMed ID: 8733696
[TBL] [Abstract][Full Text] [Related]
8. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.
Chemnitz JM; von Lilienfeld-Toal M; Holtick U; Theurich S; Shimabukuro-Vornhagen A; Krause A; Brossart P; Hallek M; Scheid C
Ann Hematol; 2012 Jan; 91(1):47-55. PubMed ID: 21584670
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.
Galaup A; Paci A
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):333-47. PubMed ID: 23157726
[TBL] [Abstract][Full Text] [Related]
10. High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.
Główka FK; Romański M; Wachowiak J
Expert Opin Investig Drugs; 2010 Oct; 19(10):1275-95. PubMed ID: 20836619
[TBL] [Abstract][Full Text] [Related]
11. Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study.
Chekerov R; Kaltenecker G; Reichert D; Göhler T; Klare P; Oskay-Özcelik G; Sauer U; Wischnik A; Vehling-Kaiser U; Becker M; Hutzschenreuter U; Ammon A; Heidrich-Lorsbach E; Sehouli J
Anticancer Res; 2015 Dec; 35(12):6869-75. PubMed ID: 26637909
[TBL] [Abstract][Full Text] [Related]
12. A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).
Sehouli J; Tomè O; Dimitrova D; Camara O; Runnebaum IB; Tessen HW; Rautenberg B; Chekerov R; Muallem MZ; Lux MP; Trarbach T; Gitsch G
J Cancer Res Clin Oncol; 2017 Mar; 143(3):541-550. PubMed ID: 27896440
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
[TBL] [Abstract][Full Text] [Related]
14. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities.
Greystoke B; Bonanomi S; Carr TF; Gharib M; Khalid T; Coussons M; Jagani M; Naik P; Rao K; Goulden N; Amrolia P; Wynn RF; Veys PA
Br J Haematol; 2008 Jun; 142(2):257-62. PubMed ID: 18492115
[TBL] [Abstract][Full Text] [Related]
15. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study.
van der Stoep MYEC; Bertaina A; Ten Brink MH; Bredius RG; Smiers FJ; Wanders DCM; Moes DJAR; Locatelli F; Guchelaar HJ; Zwaveling J; Lankester AC
Br J Haematol; 2017 Dec; 179(5):772-780. PubMed ID: 29048102
[TBL] [Abstract][Full Text] [Related]
16. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.
Holmberg LA; Demirer T; Rowley S; Buckner CD; Goodman G; Maziarz R; Klarnet J; Zuckerman N; Harrer G; McCloskey R; Gersh R; Goldberg R; Nichols W; Jacobs A; Weiden P; Montgomery P; Rivkin S; Appelbaum FR; Bensinger WI
Bone Marrow Transplant; 1998 Oct; 22(7):651-9. PubMed ID: 9818692
[TBL] [Abstract][Full Text] [Related]
17. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
Shi Y; Pan F; Han X
Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.
Główka FK; Karaźniewicz-Łada M; Grund G; Wróbel T; Wachowiak J
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S67-70. PubMed ID: 18978748
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors.
Hilger RA; Harstrick A; Eberhardt W; Oberhoff C; Skorzec M; Baumgart J; Seeber S; Scheulen ME
Cancer Chemother Pharmacol; 1998; 42(2):99-104. PubMed ID: 9654108
[TBL] [Abstract][Full Text] [Related]
20. A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG).
Reed NS; Poole CJ; Coleman R; Parkin D; Graham JD; Kaye SB; Ostrowski J; Duncan I; Paul J; Hay A;
Eur J Cancer; 2006 Jan; 42(2):179-85. PubMed ID: 16337372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
